Higher lipid accumulation product (quartile 4 vs quartile 1) was associated with an increased incidence of composite cardiovascular events (27.82% vs 19.09%, P<0.001).
Cohort (n=5,100)
Does a higher lipid accumulation product (LAP) increase the risk of incident cardiovascular events in a community-based cohort?
Higher lipid accumulation product (LAP) is significantly associated with an increased risk of cardiovascular events and severity of sleep-disordered breathing.
Absolute Event Rate: 27.82% vs 19.09%
p-value: p=<0.001
Abstract Background The lipid accumulation product (LAP) is a novel marker of adiposity linked to cardiovascular disease (CVD) risk. This study investigates the relationship between LAP and various cardiovascular outcomes, considering the influence of sleep parameters such as the apnea–hypopnea index (AHI) and oxygen saturation, in a large cohort from the Sleep Heart Health Study (SHHS). Methods We analyzed data from 5,100 participants, examining baseline characteristics, sleep parameters, and metabolic profiles. Cox regression models assessed the association between LAP and incident cardiovascular events over an average follow-up of 11.7 years. Kaplan–Meier methods evaluated event-free survival across LAP quartiles. Results Higher LAP quartiles were significantly associated with an increased AHI and a noteworthy decrease in oxygen saturation levels. The incidence of composite CVD events rose from 19.09% in quartile 1 (Q1) to 27.82% in quartile 4 (Q4) (P < 0.001). In univariate Cox regression, the highest LAP quartile was associated with elevated risks of myocardial infarction, stroke, and congestive heart failure. In multivariable models, compared with Q1, participants in Q4 had increased risks of cardiovascular death (hazard ratio HR = 1.54, 95% confidence interval CI: 1.01–2.35), myocardial infarction/procedures (HR = 1.39, 95% CI 1.03–1.88), and coronary artery bypass grafting (HR = 1.89, 95% CI 1.05–3.40). Kaplan–Meier analyses further demonstrated significantly lower event-free survival in higher LAP quartiles for several cardiovascular outcomes. Conclusion LAP emerges as a significant marker of cardiovascular risk, found to be closely associated with the severity of sleep-disordered breathing and various measures of hypoxia. Monitoring LAP levels and sleep parameters can identify individuals at higher risk for cardiovascular events, particularly those with obstructive sleep apnea, aiding targeted prevention.
Cui et al. (Sun,) conducted a cohort in cardiovascular risk and obstructive sleep apnea (n=5,100). Lipid accumulation product (LAP) vs. Quartile 1 (Q1) LAP was evaluated on composite CVD events (p=<0.001). Higher lipid accumulation product (quartile 4 vs quartile 1) was associated with an increased incidence of composite cardiovascular events (27.82% vs 19.09%, P<0.001).